Abernethy Matt
- SEC CIK
- 0001724097
In the past year, 1 open-market sale filing worth $363.3K and no purchases.
Current role at each company
- NBIX Neurocrine Biosciences IncChief Financial Officeras of Sep 15, 2026
- FATE Fate Therapeutics IncDirectoras of Jun 15, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $363.3K
- 1 filing
- Net
- −$363.3K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Abernethy Matt as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NBIX Neurocrine Biosciences Inc
Chief Financial Officer15 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Abernethy MattChief Financial Officer | SSale | −1.65K | $82.59 | −$135.9K | −9.1%16.3K after | |
| Feb 9, 2022 (view filing) | Feb 7-8 | 2 days | Abernethy MattChief Financial Officer | SSale | −4.29K | $80.53 | −$345.5K | −17.5%20.2K after | 3 lots |
| Feb 2, 2023 (view filing) | Jan 31 | 2 days | Abernethy MattChief Financial Officer | SSale | −1.28K | $109.98 | −$141.1K | −5.7%21.4K after | |
| Feb 8, 2023 (view filing) | Feb 6-8 | 2 days | Abernethy MattChief Financial Officer | SSale | −28.6K | $102.61 | −$2.93M | −53.1%25.2K after | 5 lots |
| Aug 23, 2023 (view filing) | Aug 21 | 2 days | Abernethy MattChief Financial Officer | SSale | −2.13K | $107.39 | −$229.0K | −7.3%27.1K after | 10b5-1 |
| Feb 2, 2024 (view filing) | Jan 31 | 2 days | Abernethy MattChief Financial Officer | SSale | −1.28K | $140.72 | −$180.5K | −4.3%28.3K after | 10b5-1 |
| Feb 8, 2024 (view filing) | Feb 6-8 | 2 days | Abernethy MattChief Financial Officer | SSale | −2.26K | $138.73 | −$313.5K | −6.9%30.3K after | 2 lots10b5-1 |
| Feb 15, 2024 (view filing) | Feb 13 | 2 days | Abernethy MattChief Financial Officer | SSale | −1.35K | $132.85 | −$179.6K | −4.1%31.5K after | 10b5-1 |
| May 16, 2024 (view filing) | May 14-15 | 2 days | Abernethy MattChief Financial Officer | SSale | −30.0K | $137.95 | −$4.14M | −48.8%31.5K after | 2 lots10b5-1 |
| Jul 18, 2024 (view filing) | Jul 16 | 2 days | Abernethy MattChief Financial Officer | SSale | −900 | $150.04 | −$135.0K | −2.8%31.5K after | 10b5-1 |